Literature DB >> 6308283

Antibiotic prophylaxis for genitourinary surgery in community hospitals.

S J Childs, W G Wells, S Mirelman.   

Abstract

For 92 patients who had undergone transurethral and open urologic surgery a prospective, randomized, double-blind study was done that compared the effects of ceftriaxone, a third generation cephalosporin, to placebo. The 2 groups were similar in respect to demographic characteristics. Ceftriaxone reduced significantly the incidence of postoperative infection (p less than 0.01). Of 43 patients who received ceftriaxone 2 (5 per cent) became infected compared to 15 of 49 (30 per cent) who received placebo. Patients in the placebo group who had positive postoperative urine cultures did so approximately 2 days earlier than those in the ceftriaxone group, even though the day of catheter removal averaged about 1 1/2 days later in the ceftriaxone group. There was no correlation between the incidence of fever and infection, and there was no difference between groups with regard to postoperative bleeding, or the incidence of recatheterization or rehospitalization. Average operating time, highest temperature postoperatively and number of hospital days were approximately the same in both groups. Two patients in the placebo group had serious complications and incurred approximately $11,600 in additional expenses as a result of those complications. Of these patients 1 became septic, and 1 had urinary tract and wound infections postoperatively. These data suggest that this method of antibiotic prophylaxis will not only reduce the incidence of postoperative infection in such patients, thereby reducing morbidity, mortality and hospital costs, but also may provide an additional 1 to 2 days of protection from infection for patients who require postoperative catheterization.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6308283     DOI: 10.1016/s0022-5347(17)51122-2

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Assessment of antibiotic prophylaxis prescribing patterns for TURP: A need for Canadian guidelines?

Authors:  Keith A Lawson; Jan K Rudzinski; Ingrid Vicas; Kevin V Carlson
Journal:  Can Urol Assoc J       Date:  2013 Jul-Aug       Impact factor: 1.862

Review 2.  Prophylactic antibiotics for preventing infection after continence surgery in women with stress urinary incontinence.

Authors:  Teerayut Temtanakitpaisan; Pranom Buppasiri; Pisake Lumbiganon; Malinee Laopaiboon; Siwanon Rattanakanokchai
Journal:  Cochrane Database Syst Rev       Date:  2022-03-29

Review 3.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

4.  Prophylactic chemotherapy with fosfomycin trometamol during transurethral surgery and urological manoeuvres. Results of a multicentre study.

Authors:  F di Silverio; G Ferrone; L Carati
Journal:  Infection       Date:  1990       Impact factor: 3.553

5.  A meta-analysis of randomized, controlled trials assessing the prophylactic use of ceftriaxone. A study of wound, chest, and urinary infections.

Authors:  J C Woodfield; N Beshay; A M van Rij
Journal:  World J Surg       Date:  2009-12       Impact factor: 3.352

Review 6.  Oral prophylaxis with fosfomycin trometamol in transurethral prostatectomy and urological maneuvers: literature review and personal experience.

Authors:  F P Selvaggi; M Battaglia; F S Grossi; G Disabato; L Cormio
Journal:  Infection       Date:  1992       Impact factor: 3.553

7.  Antibiotic prophylaxis for transurethral urological surgeries: Systematic review.

Authors:  Basim S Alsaywid; Grahame H H Smith
Journal:  Urol Ann       Date:  2013-04

8.  Giant bladder uric acid stone with a history of prolonged sun exposure and high protein diet in North Moluccas: Case series.

Authors:  Abdul Muthalib Pattiiha; Abdul Fuad Hadi; Sayyidati Rokhimah; Hamzah Muhammad Hafiq
Journal:  Int J Surg Case Rep       Date:  2020-07-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.